Company
Headquarters: Chongqing, China
Employees: 12,782
CN¥10.68 Billion
CNY as of Jan. 1, 2025
US$1.46 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Chongqing Taiji Industry(Group) Co.,Ltd operates in the pharmaceutical industry in China and internationally. It researches, develops, produces, and sells Chinese medicine and health products. The company offers its products in various dosage forms, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, powders, etc. It offers its products in various areas, such as digestive system, respiratory system, cardiovascular and cerebrovascular, pediatrics and gynecology, systemic anti-infective drugs, analgesia and antibiotics, orthopedics, cold clearing and cough relief, and endocrine and nervous system drugs. The company is based in Chongqing, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥13.87 B |
| EBITDA | CN¥1.05 B |
| Gross Profit TTM | CN¥5.94 B |
| Profit Margin | 4.39% |
| Operating Margin | 4.75% |
| Quarterly Revenue Growth | -16.40% |
Chongqing Taiji Industry has the following listings and related stock indices.
Stock: SSE: 600129 wb_incandescent